Surrozen (SRZN) AI Stock Analysis

• Market Cap: $72.78M
• Dividend Yield: N/A
• Average Volume (3M): 10.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.12
• Revenue Growth: N/A
• EPS Growth: 0.13%
• Country: US
• Employees: 40
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -7.43
• Shares Outstanding: 8,562,584
• 10 Day Avg. Volume: 4,758
• 30 Day Avg. Volume: 10,115
• PEG Ratio: <0.01
• Price to Book (P/B): 5.43
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.00
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: -0.51
• Enterprise Value/Gross Profit: -1.91
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: $32.00
• Price Target Upside: 263.64% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 43 Neutral
• Price Target: ―

Surrozen's overall stock score reflects significant financial challenges, including consistent losses and a weak balance sheet. While recent corporate events, such as the private placement, provide a positive outlook for liquidity, the technical indicators and valuation suggest caution. The company needs to address its financial instability and improve cash flow management to enhance its stock performance.

Positive Factors

Industry Validation

The acquisition of companies supporting the Wnt mechanism by major players like Merck and Roche provides strategic validation for Surrozen's approach in the ophthalmology Wnt platform.

Pipeline Development

The internal preclinical pipeline includes promising candidates such as SZN-8141 and SZN-8143, which combine novel approaches to address current anti-VEGF injection burdens in retinal disease patients.

Strategic Partnerships

The strategic partnership with Boehringer Ingelheim for the development of candidate SZN-413 in retinal vascular-associated diseases provides important validation for Surrozen's Wnt pathway modulation approach.

Negative Factors

Clinical Development Challenges

The discontinuation of the lead candidate SZN-043 was due to an absence of sufficient early signal of clinical benefit in severe alcohol-associated hepatitis, highlighting challenges in this area of development.

Surrozen Business Overview & Revenue Model

Company Description

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

Surrozen makes money primarily through the development and commercialization of its proprietary therapeutic candidates. The company's revenue model includes potential income from licensing agreements, collaborations, and partnerships with other pharmaceutical companies. These partnerships can provide upfront payments, milestone payments based on the achievement of specific development goals, and royalties from product sales if the therapeutics are successfully brought to market. Additionally, Surrozen may secure funding through grants and research collaborations that support its ongoing research and development efforts.

Surrozen Financial Statement Overview

Summary

Surrozen is facing significant financial challenges. Despite some revenue in 2024, the company is experiencing consistent losses and cash burn. The balance sheet shows weakening equity and a concerning liability position. The company must focus on achieving sustainable revenue growth, controlling costs, and improving cash flow management to stabilize its financial position.

Income Statement

Surrozen's income statement reveals a challenging financial trajectory. The company has seen fluctuating revenue, with a return to positive revenue in 2024, though still at a modest level. The gross profit margin is positive for 2024, but the net profit margin remains deeply negative due to significant losses. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges. Consistent losses highlight the need for revenue growth and cost management.

Balance Sheet

The balance sheet shows a concerning financial position with negative stockholders' equity in 2024, indicating potential insolvency risks. The debt-to-equity ratio cannot be calculated due to negative equity, but the presence of debt and liabilities is notable. The equity position has deteriorated significantly over time, and the high level of liabilities relative to assets suggests financial instability.

Cash Flow

Cash flow analysis reveals a negative operating cash flow, which, while improved from prior periods, still indicates cash burn. Free cash flow remains negative, though the company has managed financing activities to maintain liquidity. The operating cash flow to net income ratio suggests inefficiencies in converting income to cash, while the free cash flow to net income ratio remains unfavorable.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
11.64M	10.65M	0.00	12.50M	0.00	0.00
	Gross Profit
10.93M	9.21M	-27.23M	9.23M	-3.30M	-2.93M
	EBIT
-25.96M	-25.54M	-45.78M	-44.34M	-54.39M	-32.81M
	EBITDA
-24.96M	-25.54M	-41.13M	-42.38M	-51.35M	-31.37M
	Net Income Common Stockholders
-81.70M	-63.56M	-43.04M	-27.67M	-52.51M	-32.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
36.04M	34.56M	36.04M	75.84M	101.85M	49.18M
	Total Assets
46.08M	48.47M	46.08M	89.44M	137.17M	62.06M
	Total Debt
3.38M	8.47M	3.38M	5.60M	7.79M	9.60M
	Net Debt
-32.66M	-26.10M	-32.66M	-19.09M	-25.30M	-25.39M
	Total Liabilities
8.14M	69.85M	8.14M	13.43M	27.47M	14.77M
	Stockholders Equity
37.94M	-21.38M	37.94M	76.00M	109.70M	47.29M
Cash Flow		Free Cash Flow
-18.21M	-17.65M	-40.76M	-44.87M	-50.08M	-29.97M
	Operating Cash Flow
-18.16M	-17.63M	-40.36M	-44.15M	-48.81M	-29.10M
	Investing Cash Flow
-46.00K	-26.00K	51.72M	38.31M	-77.71M	-15.07M
	Financing Cash Flow
92.56M	16.18M	276.00K	-2.56M	124.63M	50.05M

Surrozen Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRZN, the sentiment is Neutral. The current price of 8.8 is above the 20-day moving average (MA) of 7.94, below the 50-day MA of 9.22, and below the 200-day MA of 10.37, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 52.46 is Neutral, neither overbought nor oversold. The STOCH value of 93.29 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SRZN.

Surrozen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MGNX	54 Neutral	$112.30M	―	-60.25%	―	255.31%	-141.39%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
WHWK	52 Neutral	$88.09M	13.07	17.69%	―	16.51%	―
VERU	50 Neutral	$90.59M	―	-88.03%	―	-21.28%	36.26%
ELUT	48 Neutral	$78.12M	―	149.62%	―	-18.22%	44.67%
SRZN	43 Neutral	$72.78M	―	-456.32%	―	―	0.13%
BDTX	33 Underperform	$146.71M	40.19	4.14%	―	―	33.97%

Surrozen Corporate Events

Surrozen Secures $76.4M in Private Placement Deal

On March 24, 2025, Surrozen, Inc. entered into a Securities Purchase Agreement with institutional and accredited investors for a two-tranche private placement of shares and warrants, raising approximately $76.4 million in the first tranche. The second tranche, contingent on FDA clearance of an Investigational New Drug Application by October 31, 2026, could bring an additional $98.6 million. Additionally, Tim Kutzkey was appointed as a Class I director on March 26, 2025, bringing extensive experience in biotechnology and venture capital.